EPITAC Trademark

Pharmaceutical preparations for the treatment and prevention of oncogenic and autoimmune diseases signals using protein degradation in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, pulmonology, pneumology, oncology, metabolism, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation using protein degradation for use in treating oncology indications, namely, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastrointestinal stromal tumor (GIST), Gastric, Muscle invasive bladder cancer (MIBC), Colorectal Carcinoma (CRC), and autoimmune disease, namely, Pemphigus Vulgaris, Myasthenia Gravis, Rheumatoid arthritis, and Lupus; pharmaceutical preparations for the treatment of infectious diseases, immunodeficiency diseases, metabolic disease, Urticaria, Mastocytosis, Asthma, Alzheimer’s disease, Parkinson’s Disease, Multiple sclerosis, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastrointestinal stromal tumor (GIST), Gastric, Muscle invasive bladder cancer (MIBC), Colorectal Carcinoma (CRC), and autoimmune disease, namely, Pemphigus Vulgaris, Myasthenia Gravis, Rheumatoid arthritis, and Lupus; pharmaceutical preparations, namely, targeted therapies that degrade disease driving membrane and extracellular proteins to treat oncology and autoimmune disease, namely, metabolic disease, Urticaria, Mastocytosis, Asthma, Alzheimer’s disease, Parkinson’s Disease, Multiple sclerosis, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastrointestinal stromal tumor (GIST), Gastric, Muscle invasive bladder cancer (MIBC), Colorectal Carcinoma (CRC), and autoimmune disease, namely, Pemphigus Vulgaris, Myasthenia Gravis, Rheumatoid arthritis, and Lupus

Medical and pharmaceutical research services in relation to protein degradation; pharmaceutical research and development in relation to protein degradation; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical and biopharmaceutical products; providing evaluation testing for pharmaceutical and biopharmaceutical products featuring protein degradation; pre-clinical and non-clinical evaluation testing of pharmaceutical and biopharmaceutical products; pharmaceutical and biopharmaceutical research and development featuring protein degradation for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, metabolism, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases; medical and pharmaceutical research in relation to targeted therapies that degrade disease driving membrane and extracellular proteins